These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 31379316)
41. Selexipag (Uptravi) for pulmonary arterial hypertension. Med Lett Drugs Ther; 2016 Feb; 58(1488):21-3. PubMed ID: 26859660 [No Abstract] [Full Text] [Related]
42. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function. Morrison K; Ernst R; Hess P; Studer R; Clozel M J Pharmacol Exp Ther; 2010 Oct; 335(1):249-55. PubMed ID: 20660124 [TBL] [Abstract][Full Text] [Related]
43. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039 [TBL] [Abstract][Full Text] [Related]
44. Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus. Saiki C; Kashiwado Y; Yokoyama T; Ayano M; Imabayashi K; Kawano S; Higashioka K; Kimoto Y; Fukata M; Mitoma H; Ono N; Arinobu Y; Akashi K; Horiuchi T; Niiro H Mod Rheumatol Case Rep; 2022 Jun; 6(2):183-188. PubMed ID: 35134204 [TBL] [Abstract][Full Text] [Related]
45. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag. Verlinden NJ; Walter C; Raina A; Benza RL J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036 [TBL] [Abstract][Full Text] [Related]
47. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. Hardin EA; Chin KM Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464 [TBL] [Abstract][Full Text] [Related]
48. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Coghlan JG; Channick R; Chin K; Di Scala L; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Gaine S Am J Cardiovasc Drugs; 2018 Feb; 18(1):37-47. PubMed ID: 29307087 [TBL] [Abstract][Full Text] [Related]
49. Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag. Lázaro Salvador M; Escribano Subías P; Rodriguez Padial L Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):393-394. PubMed ID: 30910272 [No Abstract] [Full Text] [Related]
50. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956 [TBL] [Abstract][Full Text] [Related]
51. Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play. Lázaro Salvador M; Akerström F; Escribano Subías P; Berenguel Senén A; Martinez Mateo V; Rodriguez Padial L Arch Bronconeumol (Engl Ed); 2019 Feb; 55(2):102-103. PubMed ID: 30060983 [No Abstract] [Full Text] [Related]
53. [Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension]. Escribano Subías P; Cea-Calvo L; Tello de Menesses R; Gómez Sánchez MA; Delgado Jiménez JF; Sáenz de la Calzada C Rev Esp Cardiol; 2003 Aug; 56(8):818-21. PubMed ID: 12892628 [TBL] [Abstract][Full Text] [Related]
54. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF; Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604 [No Abstract] [Full Text] [Related]
55. Selexipag for the treatment of pulmonary arterial hypertension. Noel ZR; Kido K; Macaulay TE Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253 [TBL] [Abstract][Full Text] [Related]
56. Selexipag for the treatment of pulmonary arterial hypertension. Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883 [TBL] [Abstract][Full Text] [Related]
57. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Ivy DD; Claussen L; Doran A Am J Cardiol; 2007 Mar; 99(5):696-8. PubMed ID: 17317374 [TBL] [Abstract][Full Text] [Related]
58. What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management? El Yafawi R; Wirth JA Curr Hypertens Rep; 2017 Oct; 19(12):97. PubMed ID: 29071454 [TBL] [Abstract][Full Text] [Related]
59. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. Orie NN; Ledwozyw A; Williams DJ; Whittle BJ; Clapp LH Prostaglandins Other Lipid Mediat; 2013 Oct; 106():1-7. PubMed ID: 23872196 [TBL] [Abstract][Full Text] [Related]
60. Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery. Morrison K; Haag F; Ernst R; Iglarz M; Clozel M J Pharmacol Exp Ther; 2018 Jun; 365(3):727-733. PubMed ID: 29588339 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]